Warren Buffet shocks Wall Street with Biogen gamble

Biogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Buffet thinks the volatile stock is worth gambling on as the company prepa

Is Tecfidera’s patent win a pyrrhic victory for Biogen?

Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a patent challenge – but will the boost mean much when the company still fac

Biogen claims victory in patent dispute with Mylan over MS d...

Biogen gears up for Alzheimer's drug launch

There are serious doubts about whether the FDA will approve Biogen’s Alzheimer’s candidate aducanumab – but is gearing up to file it with the regulator and is already looking ahead to a pot

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

FDA cues up May verdict for Roche’s SMA challenger risdiplam